PL
UTHR icon

Polianta Ltd’s United Therapeutics UTHR Stock Holding History

Polianta Ltd’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,100
Closed -$1.51M – 119
2025
Q4 		$1.51M Sell
3,100
-800
-21% -$373K 0.2% 42
2025
Q3 		$1.63M Hold
3,900
– – 0.67% 18
2025
Q2 		$1.12M Hold
3,900
– – 0.48% 66
2025
Q1 		$1.2M Buy
+3,900
New +$1.34M 0.58% 27
2022
Q2 		– Sell
-5,000
Closed -$897K – 96
2022
Q1 		$897K Buy
+5,000
New +$953K 0.59% 55
2021
Q4 		– Sell
-6,300
Closed -$1.16M – 99
2021
Q3 		$1.16M Buy
+6,300
New +$1.24M 0.54% 57
2021
Q1 		– Sell
-8,900
Closed -$1.35M – 97
2020
Q4 		$1.35M Sell
8,900
-1,800
-17% -$236K 0.75% 13
2020
Q3 		$1.08M Buy
+10,700
New +$1.17M 0.64% 59
2017
Q1 		– Sell
-8,100
Closed -$1.16M – 92
2016
Q4 		$1.16M Buy
+8,100
New +$1.03M 0.63% 32

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Polianta Ltd's UTHR Position: Q1 2026 in Review

Polianta Ltd sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 3,100 shares — an estimated $1.51M sold.

Polianta Ltd first reported a position in UTHR in Q4 2016 and held it in 9 quarters. The position peaked at $1.63M in Q3 2025. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Polianta Ltd reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Polianta Ltd sold 3,100 United Therapeutics shares in Q1 2026, an estimated $1.51M.
  • Polianta Ltd first reported a position in United Therapeutics in Q4 2016 and held it in 9 quarters.
  • Polianta Ltd's United Therapeutics position peaked at $1.63M in Q3 2025.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Polianta Ltd's 13F filing for Q1 2026, filed 16 Apr 2026.